日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

B4GALNT4-Mediated Glycosylation of PDK1 Activates the PI3K-AKT Signaling Pathway to Promote Prostate Cancer Progression

B4GALNT4介导的PDK1糖基化激活PI3K-AKT信号通路促进前列腺癌进展

Jiang, Shaoqin; Li, Mengqiang; Su, Qingfu; Dou, Ruiling; Lin, Shaoshan; Zhang, Jili; Sun, Xiaochen; Yu, Haolan; Bao, Wei; Qu, Min; Wang, Yan; Yang, Chenghua; Gao, Xu

Druggable target ATAD2 enhances the malignant progression and cooperates with E2F1 to up-regulate PDK1 expression in glioma.

可成药靶点ATAD2增强恶性进展,并与E2F1协同作用上调胶质瘤中的PDK1表达。

Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer.

突变型 p53 调节丙酮酸脱氢酶激酶 1 (PDK1) 以促进乳腺癌细胞的增殖和迁移。

Ye Yan, Ou Zuli, Li Canling, Liao Qingyu, Zeng Qian, Ju Xiaoqian, Zhang Dian, Wei Yu, Zhang Xiang, Zhang Tao, Wu Kejia

Aerobic Exercise Ameliorates Adverse Vascular Remodeling in Diabetes via PDK1/FoxO1 Axis

有氧运动通过PDK1/FoxO1轴改善糖尿病血管不良重塑

Xie, Xiang; Zhang, Zihan; Yang, Xumei; Chu, Man

Phosphoinositide-dependent kinase 1 (PDK1) in cancer: molecular insights and therapeutic strategies

癌症中的磷脂酰肌醇依赖性激酶1 (PDK1):分子机制及治疗策略

Algheribe, Shatha; Zagzoog, Ayat; Boudjelal, Mohamed; Islam, Imadul

PDK1 elevation was induced by epigenetic modifications of KDM3A and METTL16 to mediate TKI resistance and cancer development

PDK1 水平升高是由 KDM3A 和 METTL16 的表观遗传修饰诱导的,从而介导 TKI 耐药性和癌症发展。

Zhou, Zhihao; Zhang, Ruike; Zhang, Zhaoyang; Zhang, Liyuan; Wang, Wei; Liu, Wenjing; Zhang, Chunyang; Lin, Gen; Yu, Weimiao; Xu, Bo; Wang, Lin; Jiang, Bing-Hua

Correction: SPOP‑mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions

更正:SPOP介导的PDK1泛素化和降解抑制AKT激酶活性和致癌功能

Jiang, Qiwei; Zheng, Nana; Bu, Lang; Zhang, Xiaomei; Zhang, Xiaoling; Wu, Yuanzhong; Su, Yaqing; Wang, Lei; Zhang, Xiaomin; Ren, Shancheng; Dai, Xiangpeng; Wu, Depei; Xie, Wei; Wei, Wenyi; Zhu, Yasheng; Guo, Jianping

PDK1 neddylation by Smurf1 drives Akt activation

Smurf1介导的PDK1 NEDDylation修饰驱动Akt激活

Manne, Rajesh Kumar; Kant, Rajni; Lin, Hui-Kuan

FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions

在缺氧条件下,FTO通过m6A/YTHDF3/PDK1轴激活PD-L1,促进乳腺癌的免疫抑制。

Wang, Siyu; Zhang, Xingda; Chen, Quanrun; Wu, Hao; Cao, Shihan; Zhao, Shilu; Li, Guozheng; Wang, Jianyu; Gong, Yajie; Wang, Xinheng; Pang, Da; Gao, Song

EMC2 promotes breast cancer progression and enhances sensitivity to PDK1/AKT inhibition by deubiquitinating ENO1

EMC2通过去泛素化ENO1促进乳腺癌进展并增强对PDK1/AKT抑制剂的敏感性。

Xiao, Shihan; Jiang, Shangxuan; Wen, Chengxu; Wang, Han; Nie, Wenxiang; Zhao, Jianguo; Zhang, Bo